Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.91 USD | +4.72% | +2.06% | +22.48% |
Mar. 06 | Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating | MT |
Mar. 04 | Transcript : Cara Therapeutics, Inc., Q4 2023 Earnings Call, Mar 04, 2024 |
Financials (USD)
Sales 2024 * | 5.59M | Sales 2025 * | 3.67M | Capitalization | 47.5M |
---|---|---|---|---|---|
Net income 2024 * | -64M | Net income 2025 * | -81M | EV / Sales 2024 * | 6.64 x |
Net cash position 2024 * | 10.4M | Net Debt 2025 * | 29.1M | EV / Sales 2025 * | 20.9 x |
P/E ratio 2024 * |
-0.74
x | P/E ratio 2025 * |
-0.78
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.41% |
Latest transcript on Cara Therapeutics, Inc.
1 day | +19.01% | ||
1 week | -3.74% | ||
Current month | +2.21% | ||
1 month | -8.09% | ||
3 months | +31.63% | ||
6 months | -48.27% | ||
Current year | +16.96% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 18-08-05 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 22-09-11 |
Joana Goncalves
CTO | Chief Tech/Sci/R&D Officer | 50 | 18-10-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 10-06-30 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-07-15 |
Helen Boudreau
BRD | Director/Board Member | 58 | 23-08-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.20% | 29 M€ | +37.94% | - | |
1.29% | 13 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.91 | +4.72% | 636 574 |
24-03-27 | 0.869 | +19.01% | 569,385 |
24-03-26 | 0.7302 | -10.94% | 711,831 |
24-03-25 | 0.8199 | -7.18% | 470,713 |
24-03-22 | 0.8833 | -0.93% | 204,803 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.96% | 47.5M | |
+0.44% | 90.27B | |
+10.00% | 44.05B | |
-16.40% | 31.45B | |
+44.36% | 23.35B | |
-8.10% | 16.72B | |
-25.64% | 15.09B | |
-9.03% | 12.82B | |
-9.37% | 11.95B | |
+98.58% | 7.67B |